SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity
Background The coronavirus disease 2019 (COVID-19) pandemic placed unprecedented pressure on various healthcare systems, including departments that use immunotherapies such as chimeric antigen receptor (CAR) T-cell therapy and immunosuppression therapy in organ transplantation units. The true impact...
Saved in:
| Main Authors: | Jianfeng Zhou, Meifang Han, Jianping Zhao, Jia Wei, Fankai Meng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000862.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals
by: Núria Mayola Danés, et al.
Published: (2025-05-01) -
Analysis of the humoral and cell-mediated immune response in heterologous and homologous SARS-CoV-2 revaccination
by: O. M. Drapkina, et al.
Published: (2023-11-01) -
Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed families
by: Alex Dulovic, et al.
Published: (2025-07-01) -
An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
by: Isabel H. Gonzalez-Bocco, et al.
Published: (2025-10-01) -
Humoral and Cellular Immune Responses to SARS-CoV-2 in Participants with Head and Neck Cancer
by: Luminita Mărutescu, et al.
Published: (2025-06-01)